Journal of Antimicrobial Chemotherapy (2002) 49, 275-282
© 2002 The British Society for Antimicrobial Chemotherapy
Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis
a Sezione di Microbiologia e Virologia, Dipartimento di Scienze Chirurgiche e Trapianti d'Organo, Università di Cagliari, Viale Frà Ignazio 38, 09123 Cagliari; b Dipartimento di Tossicologia, Università di Cagliari, Cagliari; c Laboratorio di Analisi Ospedale SS. Trinità ASL 8, Cagliari, Italy
The activities of six derivatives of a new class of isonicotinoylhydrazones were investigated in vitro against Mycobacterium tuberculosis H37Rv ATCC 27294, isoniazid-resistant M. tuberculosis ATCC 35822, rifampicin-resistant ATCC 35838, pyrazinamide-resistant ATCC 35828, streptomycin-resistant ATCC 35820 and 16 clinical isolates of M. tuberculosis. Several compounds showed interesting antimycobacterial activity against both ATCC strains and clinical isolates, but were less active against isoniazid-resistant M. tuberculosis. Combinations of five isonicotinoylhydrazone derivatives and rifampicin, ethambutol, para-aminosalicylic acid, isoniazid and clofazimine were also investigated against M. tuberculosis H37Rv ATCC 27294 and against ATCC drug-resistant strains. Addition of sub-MICs of some isonicotinoylhydrazone derivatives resulted in a four- to 16-fold reduction in MICs of ethambutol, para-aminosalicylic acid and rifampicin with fractional inhibitory concentrations (FICs) ranging between 0.17 and 0.37, suggesting a synergic interaction against M. tuberculosis H37Rv. Increased activity was also observed with other combinations (FICs 0.53–0.75), including isoniazid, and a synergic interaction between one of the isonicotinoylhydrazone derivatives and isoniazid (FIC 0.26) was shown against isoniazid-resistant M. tuberculosis ATCC 35822, whereas no effects were observed on combining the isonicotinoylhydrazones with clofazimine. The ability of isonicotinoylhydrazones to inhibit specifically the growth of M. tuberculosis, the high selectivity index and their ability to enhance the activity of standard antituberculous drugs in vitro indicate that they may serve as promising lead compounds for future drug development for the treatment of M. tuberculosis infections.
* Corresponding author. Tel/Fax: +39-07-066-8001; E-mail: adelogu{at}unica.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Mathys, R. Wintjens, P. Lefevre, J. Bertout, A. Singhal, M. Kiass, N. Kurepina, X.-M. Wang, B. Mathema, A. Baulard, et al. Molecular Genetics of para-Aminosalicylic Acid Resistance in Clinical Isolates and Spontaneous Mutants of Mycobacterium tuberculosis Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2100 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hearn and M. H. Cynamon Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base J. Antimicrob. Chemother., February 1, 2004; 53(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|